← Patent-cliff monitor small molecule IQIRVO ELAFIBRANOR
Loss of exclusivity March 2044 latest FDA-listed patent expiry
Company IPSEN BIOPHARMACEUTICALS INC
Drug detail Brand name IQIRVO Active ingredient ELAFIBRANOR Strength 80MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2024 Marketing status RX
Listed patents Patent Expires Type 12673035 March 2044 product 11850223 March 2037 use U-1854 11331292 March 2037 use U-1854 11185519 March 2037 use U-3955 12310935 March 2037 use U-1854 12295928 March 2037 use U-1854 12295927 March 2037 use U-1854 12233038 March 2037 use U-1854 11857523 March 2037 use U-3955 12589086 March 2037 use U-4473
Regulatory exclusivity Code Expires ODE-486 June 2031 NCE June 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.